# Ancient and Emerging Nanostructures for Innovations to Fight Head and Neck Cancer

**Authors:** Nina Kummer, Ömür Acet, Burcu Önal Acet, Mike Blueggel, Aya Khamis, Désirée Gül, Shirley K. Knauer, Roland H. Stauber

PMC · DOI: 10.3390/cells15040339 · 2026-02-13

## TL;DR

This paper explores how ancient and new nanostructures can target the tumor microenvironment to improve treatment for head and neck cancer.

## Contribution

The paper integrates ancient and emerging nanostructures to reshape therapeutic strategies for head and neck squamous cell carcinoma.

## Key findings

- Ancient nanostructures like biopolymers and plant-derived nanovesicles modulate cellular signaling and immune responses.
- Emerging nanosystems enable precise targeting of DNA damage response and redox homeostasis in HNSCC.
- Integrated nano-platforms offer potential to reprogram the tumor microenvironment and overcome therapy resistance.

## Abstract

What are the main findings?
Head and neck squamous cell carcinoma (HNSCC) is characterized by a highly resistant tumor microenvironment involving hypoxia, immune suppression, and stromal remodeling.Emerging nanostructures—including nanobodies, engineered exosomes, DNA origami, and (stimuli-)responsive nanoparticles—enable precise, targeted modulation of HNSCC pathobiology.

Head and neck squamous cell carcinoma (HNSCC) is characterized by a highly resistant tumor microenvironment involving hypoxia, immune suppression, and stromal remodeling.

Emerging nanostructures—including nanobodies, engineered exosomes, DNA origami, and (stimuli-)responsive nanoparticles—enable precise, targeted modulation of HNSCC pathobiology.

What are the implications of the main findings?
Targeted modulation of the tumor and its microenvironment via advanced nanostructures offers a promising strategy to fight HNSCC.For clinical translation, critical challenges remain including ensuring safety, controlled responsiveness, and overall feasibility, which must be addressed to enable precision oncology approaches.

Targeted modulation of the tumor and its microenvironment via advanced nanostructures offers a promising strategy to fight HNSCC.

For clinical translation, critical challenges remain including ensuring safety, controlled responsiveness, and overall feasibility, which must be addressed to enable precision oncology approaches.

Head and neck squamous cell carcinoma (HNSCC) remains a major global health challenge due to its aggressive behavior, late-stage diagnosis, and high incidence of therapy resistance. At the cellular level, these clinical limitations are driven by profound alterations in oncogenic signaling, stress adaptation, DNA damage response pathways, and immune regulation within the tumor microenvironment. Advances in nanotechnology offer powerful opportunities to address these challenges by enabling targeted interference with cellular processes that govern tumor growth, survival, and therapy resistance. “Ancient” (i.e., established, long-studied) nanostructures, including mineral-based nanoparticles, natural biopolymers, and plant-derived nanovesicles, provide inherently biocompatible and bioactive platforms capable of modulating cellular signaling, redox balance, and immune responses. In parallel, emerging nanosystems—such as nanobodies, engineered exosomes, DNA origami, and stimuli-responsive smart nanoparticles—allow precise molecular targeting, controlled cargo release, and direct manipulation of intracellular pathways and intercellular communication. This manuscript synthesizes historical and contemporary developments in nanostructure design, highlighting how the integration of ancient materials with advanced nanotechnology can reshape therapeutic strategies for HNSCC. By targeting key cellular and microenvironmental processes, including DNA damage response signaling, redox homeostasis, immune regulation and stress-adaptive survival mechanisms, rather than drug delivery alone, these integrated nano-platforms offer promising avenues to overcome resistance mechanisms, reprogram the tumor microenvironment, and improve therapeutic precision and patient outcomes.

## Linked entities

- **Diseases:** head and neck squamous cell carcinoma (MONDO:0010150), HNSCC (MONDO:0010150)

## Full-text entities

- **Genes:** FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, EPHB2 (EPH receptor B2) [NCBI Gene 2048] {aka BDPLT22, CAPB, DRT, EK5, EPHT3, ERK}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, WNT7B (Wnt family member 7B) [NCBI Gene 7477], MUL1 (mitochondrial E3 ubiquitin protein ligase 1) [NCBI Gene 79594] {aka C1orf166, GIDE, MAPL, MULAN, RNF218}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, LCP1 (lymphocyte cytosolic protein 1) [NCBI Gene 3936] {aka CP64, HEL-S-37, L-PLASTIN, LC64P, PLS2}, FZD5 (frizzled class receptor 5) [NCBI Gene 7855] {aka C2orf31, HFZ5, MCOPCB11}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, RET (ret proto-oncogene) [NCBI Gene 5979] {aka CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, FZD8 (frizzled class receptor 8) [NCBI Gene 8325] {aka FZ-8, hFZ8}
- **Diseases:** inflammation (MESH:D007249), injury to (MESH:D014947), pancreatic tumor (MESH:D010190), Cancer (MESH:D009369), HNCs (MESH:D006258), metastatic (MESH:D000092182), Hypoxic (MESH:D002534), laryngeal cancer (MESH:D007822), hypoxemia (MESH:D000860), HNSCC (MESH:D000077195), metastasis (MESH:D009362), colon cancer (MESH:D015179), deaths (MESH:D003643), tumorigenic (MESH:D002471), infection (MESH:D007239), oral mucositis (MESH:D013280), cytotoxicity (MESH:D064420), ovarian cancer (MESH:D010051)
- **Chemicals:** MMT (MESH:C009907), gold (MESH:D006046), platinum (MESH:D010984), Metal (MESH:D008670), kaolinite (MESH:D007616), Alginate (MESH:D000464), oxygen (MESH:D010100), CS (MESH:D048271), Paclitaxel (MESH:D017239), laponite (MESH:C524813), lactate (MESH:D019344), polysaccharide (MESH:D011134), polymer (MESH:D011108), polyelectrolyte (MESH:D000071228), chitin (MESH:D002686), 5-FU (MESH:D005472), water (MESH:D014867), Ato (MESH:D053626), amides (MESH:D000577), PAA (MESH:C006903), iron (MESH:D007501), BLM (MESH:D001761), CaP (MESH:C020243), Fe3O4 (MESH:C000499), chloride (MESH:D002712), cholesterol (MESH:D002784), bentonite (MESH:D001546), curcumin (MESH:D003474), Cisplatin (MESH:D002945), BioRender (-), disulfide (MESH:D004220), Dox (MESH:D004317), Silica (MESH:D012822), thiol (MESH:D013438), CpG (MESH:C015772), pirfenidone (MESH:C093844), carbohydrate (MESH:D002241), cetuximab (MESH:D000068818), polycaprolactone (MESH:C016240), GSH (MESH:D005978), polyphenols (MESH:D059808), diols (MESH:D011276), lipid (MESH:D008055), cellulose (MESH:D002482), alcohol (MESH:D000438), Poly(N-isopropylacrylamide (MESH:C052970), lanthanide (MESH:D028581), ROS (MESH:D017382), CpG oligonucleotides (MESH:C408982), flavonoids (MESH:D005419), sepiolite (MESH:C001671), glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Human papillomavirus (species) [taxon 10566], Panax ginseng (Asiatic ginseng, species) [taxon 4054], Nicotiana tabacum (American tobacco, species) [taxon 4097], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Homo sapiens (human, species) [taxon 9606], Human papillomavirus 16 (serotype) [taxon 333760], PX clade (clade) [taxon 569578]
- **Cell lines:** HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_2959), A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), FaDu — Homo sapiens (Human), Hypopharyngeal squamous cell carcinoma, Cancer cell line (CVCL_1218), SW480 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0546), HS5 — Homo sapiens (Human), Transformed cell line (CVCL_3720), LAMA84 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_0388), CAL27 — Homo sapiens (Human), Tongue adenosquamous carcinoma, Cancer cell line (CVCL_1107), HeLa cancer — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939986/full.md

---
Source: https://tomesphere.com/paper/PMC12939986